Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Merck
Medtronic
Colorcon
UBS
Johnson and Johnson

Generated: July 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,579,377

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,579,377
Title:Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Abstract:Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefore, advantageously topically applicable gels, creams or lotions.
Inventor(s): Graeber; Michael (Lawrenceville, NJ), Czernielewski; Janusz (Biot, FR)
Assignee: Galderma Research & Development (Biot, FR)
Application Number:10/937,612
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,579,377
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,579,377
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,579,377

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 AB RX Yes Yes ➤ Sign Up ➤ Sign Up TOPICAL TREATMENT OF ACNE VULGARIS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,579,377

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France02 03070Mar 12, 2002

International Family Members for US Patent 7,579,377

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 038924 ➤ Sign Up
Austria 417610 ➤ Sign Up
Austria 432072 ➤ Sign Up
Australia 2003216898 ➤ Sign Up
Australia 2008203279 ➤ Sign Up
Brazil 0307550 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Daiichi Sankyo
Teva
Healthtrust
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.